Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-tenascin monoclonal antibody 81C6-I-131

Next Previous
X
Search
Drug Profile

Anti-tenascin monoclonal antibody 81C6-I-131

Alternative Names: I-131 mAb81c6; Neuradiab

Latest Information Update: 01 Aug 2012

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University Medical Center
  • Developer Bradmer Pharmaceuticals
  • Class Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 30 Jul 2012 Bradmer pharmaceuticals terminates its licence agreement with Duke Univeresity
  • 19 Nov 2008 Efficacy data from 2 phase II trials in newly diagnosed glioblastoma multiforme released by Bradmer
  • 23 Jul 2008 Bradmer Pharmaceuticals initiates enrolment in the GLASS-ART phase III trial for primary glioblastoma multiforme in the US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top